Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21690111 | 0.89 | ALDH1A1 (0.69) | ALDH1A1HPGDMEN1KMT2AALOX12 | |
| SCHEMBL1437082 | 0.84 | MEN1 (0.62) | ALDH1A1HPGDMEN1KMT2AALOX12 | |
| SCHEMBL1004083 | 0.84 | RXFP1 (0.68) | ALDH1A1HPGDMEN1KMT2AALOX12 | |
| SCHEMBL16677971 | 0.84 | MAPT (0.67) | ALDH1A1HPGDMEN1KMT2AMAPK1 | |
| SCHEMBL9903880 | 0.84 | PKM (0.62) | ALDH1A1HPGDMEN1KMT2AALOX12 | |
| SCHEMBL20392703 | 0.84 | LMNA (0.67) | ALDH1A1HPGDMEN1KMT2AMAPK1 | |
| SCHEMBL1447260 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HPGDMEN1KMT2AMAPK1 | |
| SCHEMBL2451128 | 0.82 | ALDH1A1 (0.66) | ALDH1A1HPGDMEN1KMT2AALOX12 | |
| SCHEMBL31650388 | 0.82 | ALDH1A1 (0.60) | ALDH1A1HPGDMEN1KMT2AALOX12 | |
| SCHEMBL6497794 | 0.82 | MEN1 (0.60) | ALDH1A1HPGDMEN1KMT2AALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-1045841-B1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | CHOONGWAE PHARMA CORP (KR) | 2002-12-04 | — | — | EP | claimed |
| US-6262083-B1 | Genipin derivative having liver protection activity | CHOONGWAE PHARMA CORPORATION (KR) | 2001-07-17 | — | — | US | claimed |
| EP-1045841-A1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | Choongwae Pharma Corporation (KR) | 2000-10-25 | — | — | EP | claimed |
| WO-1999023090-A1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | CHOONGWAE PHARMA CORPORATION (KR) | 1999-05-14 | — | — | WO | claimed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | disclosed |
| US-9296762-B2 | Complexing agents and corresponding lanthanide complexes | CISBIO BIOASSAYS (FR) | 2016-03-29 | — | — | US | disclosed |
| WO-2016004093-A2 | THERAPEUTIC COMPOSITIONS INCLUDING GALECTIN-3 INHIBITORS AND USES THEREOF | STEALTH BIOTHERAPEUTICS CORP (MC) | 2016-01-07 | — | — | WO | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | ALDH1A1 357/4885HPGD 1486/4885MEN1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.